ReviewFrontiers in microbiology2024
Diabetes and gut microbiome.
Review in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Review
- Associations of Diabetes Mellitus Status and Geriatric Nutritional Risk Index with the Gut Microbiota in Nursing-Home Residents.Nutrients · 2026Article
- Metagenomic Insights into Gut Microbiota Alterations FollowingInternational journal of molecular sciences · 2026Article
- Intestinal Microbiota in Diabetes-Does the Pathomechanism and Diversity Depend on the Type of Diabetes and Coexisting Metabolic Disorders?Journal of clinical medicine · 2026Review
- Effects of the Synbiotic Formulation EDC-HHA01 on Glucose Regulation in Adults with Type 2 Diabetes and Prediabetes: A Randomized, Placebo-Controlled Study.Microorganisms · 2026Article
- Community-Acquired Pneumonia in Patients With Diabetes: Narrative Review.JMIR diabetes · 2026Review
- Salivary microbiota and clinical periodontal measures predicting cardiometabolic disease mortality: A nationwide survey.Journal of periodontology · 2026Article
- Oncometabolites and Hypoxia-Regulated Exosomes Shape HIF-Driven Macrophage Programs Across Type 2 Diabetes, Atherosclerosis, and Cancer.International journal of molecular sciences · 2026Review
- Association of a Dietary Index for Gut Microbiota With Epilepsy Among US Adults Aged 40 and Over: A Cross-Sectional Study.Behavioural neurology · 2026Article
- Childhood type 1 diabetes mellitus and gut microbiota: from microbiome characteristics to prevention and treatment strategies.Frontiers in cellular and infection microbiology · 2026Review
- DifferentialActa biochimica Polonica · 2026Article
- The role of the gut microbiota in obesity-related metabolic diseases in the pediatric population.Pediatric endocrinology, diabetes, and metabolism · 2026Review
- Comparative analysis of gut microbiota composition in the fecal samples from type 2 diabetes mellitus patients and healthy individuals: a case control study.Iranian journal of microbiology · 2025Article
- Review
- Crosstalk Among Gut Microbiota, Microbial Metabolites, and Inflammatory Cytokines: Current Understanding and Future Directions.Foods (Basel, Switzerland) · 2025Review
- SGLT-2 Inhibitors and Metabolic Outcomes: A Primary Data Study Exploring the Microbiota-Diabetes Connection.Metabolites · 2025Article
- Type 1 Diabetes Mellitus and Vitamin D.International journal of molecular sciences · 2025Review
- Natural Antidiabetic Agents: Insights into Ericaceae-Derived Phenolics and Their Role in Metabolic and Oxidative Modulation in Diabetes.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Intestinal Microbiota Composition in Patients with Type 2 Diabetes and Effects of Oral Antidiabetics.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus represents a significant global health problem. The number of people suffering from this metabolic disease is constantly rising and although the incidence is heterogeneous depending on region, country, economic situation, lifestyle, diet and level of medical care, it is increasing worldwide, especially among youths and children, mainly due to lifestyle and environmental changes. The pathogenesis of the two most common subtypes of diabetes mellitus, type 1 (T1DM) and type 2 (T2DM), is substantially different, so each form is characterized by a different causation, etiology, pathophysiology, presentation, and treatment. Research in recent decades increasingly indicates the potential role of the gut microbiome in the initiation, development, and progression of this disease. Intestinal microbes and their fermentation products have an important impact on host metabolism, immune system, nutrient digestion and absorption, gut barrier integrity and protection against pathogens. This review summarizes the current evidence on the changes in gut microbial populations in both types of diabetes mellitus. Attention is focused on changes in the abundance of specific bacterial groups at different taxonomic levels in humans, and microbiome shift is also assessed in relation to geographic location, age, diet and antidiabetic drug. The causal relationship between gut bacteria and diabetes is still unclear, and future studies applying new methodological approaches to a broader range of microorganisms inhabiting the digestive tract are urgently needed. This would not only provide a better understanding of the role of the gut microbiome in this metabolic disease, but also the use of beneficial bacterial species in the form of probiotics for the treatment of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.